Efficacy and safety of telaprevir, a new protease inhibitor, for difficult‐to‐treat patients with genotype 1 chronic hepatitis C-Reference-Cited by-同舟云学术

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult‐to‐treat patients with genotype 1 chronic hepatitis C

Published:2011-11-08 Issue:2 Volume:19 Page:
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:Journal of Viral Hepatitis

Author:

Hayashi N.¹,Okanoue T.²,Tsubouchi H.³,Toyota J.⁴,Chayama K.⁵,Kumada H.⁶

Affiliation:

1. Kansai‐Rosai Hospital, Hyogo, Japan

2. Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan

3. Department of Digestive and Life‐style Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

4. Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan

5. Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan;

6. Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2893.2011.01528.x

Reference22 articles.

1. World Health Organization.Initiative for vaccine research (IVR). [http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html]

2. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

3. Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin

4. Diagnosis, management, and treatment of hepatitis C: An update

5. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir;Biochemistry and Biophysics Reports;2022-07

2. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral;Global Health & Medicine;2021-10-31

3. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct‐acting antiviral agents in chronic hepatitis C virus‐infected patients;Journal of Gastroenterology and Hepatology;2020-10-11

4. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b;Gut and Liver;2018-03-15

5. Diagnosis and Management of Hepatitis C Infection in Primary Care Settings;Journal of General Internal Medicine;2018-01-19